You are here
APOIMMUNE, INC
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates
Amount: $803,836.00DESCRIPTION (provided by applicant): Pancreatic islet transplantation is a viable approach for the treatment of type 1 diabetes (T1D). However, this therapeutic approach suffers from graft rejection. ...
STTRPhase I2010Department of Health and Human Services National Institutes of Health -
ApoVax104-HPV as a Novel Vaccine for Cervical Cancer
Amount: $1,636,800.00DESCRIPTION (provided by applicant): Cervical cancer is one of the most common cancers affecting women and is a worldwide health problem. Unlike most cancers, cervical cancer is caused by a virus - t ...
SBIRPhase II2008Department of Health and Human Services National Institutes of Health -
ApoVax104-TB as a Novel Vaccine for Tuberculosis
Amount: $821,483.00DESCRIPTION (provided by applicant): The objective of this NIAID Advanced STTR Phase I proposal is to combine the strengths of academic investigators from the fields of immunology and animal disease m ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
ApoFasL: a Novel Immunotherapeutic for T1D
Amount: $421,676.00DESCRIPTION (provided by applicant): Type 1 Diabetes (T1D) is an autoimmune disease that targets insulin secreting pancreatic beta cells for destruction and remains a major cause of morbidity and mort ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
ApoVax-SVN as a Novel Vaccine for Cancer Immunotherapy
Amount: $328,300.00DESCRIPTION (provided by applicant): The main objective of this proposal is to develop a novel cancer vaccine, ApoVax-SVN(tm) based on the use of a proprietary costimulatory chimeric ligand, 4-1BBL, d ...
STTRPhase I2007Department of Health and Human Services National Institutes of Health -
ApoVax104-HPV as a Novel Vaccine for Cervical Cancer
Amount: $300,000.00DESCRIPTION (provided by applicant): Various cancer vaccines based on tumor associated antigens (TAAs) or tumor specific antigens (TSAs) have shown efficacy in preclinical models. However, their ther ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
Chimeric CD80-SA as a Novel Cancer Vaccine
Amount: $750,804.00DESCRIPTION (provided by applicant): Cancer is one of the major causes of death in the U.S. and many developed countries with an estimated economic burden of over 100 billion dollars in direct and ind ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
A NOVEL ADJUVANT FOR TUMQR VACCINATION
Amount: $100,000.00DESCRIPTION (provided by applicant): Cancer continues to be a leading cause of death in the U.S. and in many other countries. Cancers develop and spread within the body when tumor cells are not detec ...
STTRPhase I2004Department of Health and Human Services National Institutes of Health -
A NOVEL ADJUVANT FOR TUMQR VACCINATION
Amount: $100,000.00DESCRIPTION (provided by applicant): Cancer continues to be a leading cause of death in the U.S. and in many other countries. Cancers develop and spread within the body when tumor cells are not detec ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
A NOVEL APPROACH TO PREVENT GRAFT-VERSUS HOST DISEASE
Amount: $100,000.00DESCRIPTION (provided by the applicant): Bone marrow transfusion (BMT) holds the potential to cure many blood diseases. However, BMT recipients often develop graft-versus-host disease (GvHD), a life-t ...
SBIRPhase I2002Department of Health and Human Services National Institutes of Health
